Biotech & Pharma

Biogen stops part of an MS trial; Merck reports more Enflonsia data

25 sec read18 views0 listens

Biogen has halted the combination therapy segment of its multiple sclerosis (MS) trial, impacting ongoing research and investor confidence in its treatment approach. This decision underscores the high stakes and uncertainties in developing effective MS treatments, advising content creators to emphasize the dynamic nature of clinical trials and the importance of scientific rigor when reporting on medical advancements.

Read the full article at Endpoints News

Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.

You Might Like

Tech & Gadgets10 hours ago27 sec read

Canada poaches 64 global scholars in bid to bolster domestic talent pipeline

Canada has secured the relocation of 64 international academics, primarily from the U.S., to its universities under a new $1.7 billion initiative aimed at boosting research and innovation in key fields like AI, health, and environmental science. This...

Ali Nemati

Real Estate & Home1 day ago27 sec read

Unstable rental housing creating lifelong disadvantages for children, new study warns

A new study by the Australian Housing and Urban Research Institute reveals that children in rental homes move frequently and are more likely to face poor living conditions, negatively impacting their development. This instability affects physical and...

Ali Nemati

Cybersecurity1 day ago27 sec read

Canadian supercomputers are transforming drug discovery: Can they deliver medicines faster?

Researchers at Simon Fraser University have developed an AI framework called CGFlow, which accelerates the design of drug molecules by ensuring they can be synthesized in a laboratory. This advancement is crucial for reducing the time and cost associ...

Ali Nemati